- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05243355
Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC
February 14, 2022 updated by: Qilu Hospital of Shandong University
A Prospective, Single-arm, Phase II Study of Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Advanced (Stage IIIB-IV) Squamous Non-small Cell Lung Cancer
This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Envafolimab combined with standard platinum containing dual drug chemotherapy and Recombinant Human Endostatin in patients with advanced (stage IIIB-IV) squamous non-small cell lung cancer.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
46
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lian Liu, Doctor
- Phone Number: 18560082903
- Email: tounao@126.com
Study Locations
-
-
-
Jinan, China
- Not yet recruiting
- Shandong Cancer Hospital
-
Contact:
- Jie Liu, Doctor
-
Principal Investigator:
- Jie Liu, Doctor
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Recruiting
- Qilu Hospital of Shandong Univertisy
-
Contact:
- Lian Liu, Doctor
-
Principal Investigator:
- Lian Liu, Doctor
-
Sub-Investigator:
- Yanguo Liu, Doctor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed written informed consent;
- Aged 18-75 years old;
- Histologically or cytologically confirmed, locally advanced (Stage IIIB/C) not amenable to curative surgery or radiotherapy, or metastatic/recurrent (Stage IV) squamous NSCLC according to American Joint Committee on Cancer, 8th Edition;
- At least 1 measurable lesion as defined by RECIST v1.1;
- ECOG performance status 0-1;
- No systematic antitumor treatment for advanced / metastatic diseases has been received in the past;
- Life expectancy sup 3 months;
- Adequate organ function;
- For female subjects of childbearing age, urine or serum pregnancy test shall be conducted 3 days before receiving the first study drug administration, and the result is negative;
- The subject and the subject's sexual partner need to use a medically approved contraceptive measure during the study treatment period and within 6 months after the end of the study treatment period.
Exclusion Criteria:
- Histology was non squamous cell NSCLC. Mixed cell types must distinguish the dominant cell morphology (squamous cell carcinoma components > 50% can be included in the group); If there are small cell carcinoma, neuroendocrine carcinoma and sarcoma, they can not be included in the group;
- EGFR sensitive mutations or ALK rearrangements;
- Imaging (CT or MRI) showed that the tumor invaded large blood vessels or it was judged that the tumor was very likely to invade important blood vessels and cause fatal bleeding during the follow-up study;
- Concurrent participation in another clinical trial;
- Have previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs that stimulate or co inhibit T cell receptors (e.g., CTLA-4, OX-40, CD137);
- Received Chinese patent medicine with anti-tumor indications or drugs with immunomodulatory effect (thymosin, interferon, interleukin, etc.) within 2 weeks, or major surgical treatment within 3 weeks before the first administration;
- There are active hemoptysis, active diverticulitis, abdominal abscess, gastrointestinal obstruction and peritoneal metastasis that need clinical intervention;
- Grade III-IV congestive heart failure (New York Heart Association classification), poorly controlled and clinically significant arrhythmia;
- Any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, occurred within 6 months before enrollment;
- Known allergic reactions to PD-1/L1 monoclonal antibodies, taxanes, cisplatin or carboplatin, recombinant human endostatin active ingredients and or any excipients;
- Patients requiring long-term systemic use of corticosteroids;
- Symptomatic central nervous metastasis;
- Active infection requiring treatment or systemic anti infective drugs used within one week before the first administration;
- Not fully recovered from toxicity and/or complications caused by any intervention before starting treatment (i.e. ≤ grade 1 or reaching baseline, excluding fatigue or hair loss);
- Known HIV infection;
- Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number detected greaterthan the upper limit of normal value in the laboratory of the research center);
- Active HCV infected;
- Live vaccine was administered within 30 days before the first administration;
- Pregnant or lactating women;
- Medical history or disease evidence, abnormal treatment or laboratory test values that may interfere with the test results, prevent the subjects from participating in the whole study, or other situations that the researchers believe are not suitable for inclusion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: "Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin"
Envafolimab: 300 mg,D1,Q3W, until PD or intolerable toxicity.
Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w.
Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles.
Recombinant Human Endostatin:210mg,CIV 72h,d1-3,Q3W,4-6 cycles in total.
|
Envafolimab: 300 mg,D1,Q3W,until PD or intolerable toxicity Chemotherapy: Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w; Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles in total. Recombinant Human Endostatin:210mg,CIV 72h,d1-3,Q3W,4-6 cycles in total. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1 year PFS rate
Time Frame: 12 months after the last subject participating in
|
12-month progression free survival in ITT population
|
12 months after the last subject participating in
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: 24 months after the last subject participating in
|
The proportion of subjects with complete response (CR) and partial response (PR) in total subjects
|
24 months after the last subject participating in
|
DOR
Time Frame: 24 months after the last subject participating in
|
DoR (per RECIST 1.1) is defined as the time from the date for first documented response of complete response (CR) or partial response (PR) to the date of first documented of disease progression or death, whichever occurs first.
|
24 months after the last subject participating in
|
PFS
Time Frame: 24 months after the last subject participating in
|
Progression-free survival (PFS per RECIST 1.1) is defined as the time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first
|
24 months after the last subject participating in
|
OS
Time Frame: 24 months after the last subject participating in
|
OS is defined as the time from the starting date of study drug to the date of death due to any cause.
|
24 months after the last subject participating in
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 3, 2021
Primary Completion (Anticipated)
December 3, 2023
Study Completion (Anticipated)
December 3, 2024
Study Registration Dates
First Submitted
December 16, 2021
First Submitted That Met QC Criteria
February 14, 2022
First Posted (Actual)
February 17, 2022
Study Record Updates
Last Update Posted (Actual)
February 17, 2022
Last Update Submitted That Met QC Criteria
February 14, 2022
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Endostatins
Other Study ID Numbers
- SMA-NSCLC-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Non-small Cell Lung Cancer
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
AIO-Studien-gGmbHAstraZenecaTerminatedNSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR MutationGermany
-
Western Regional Medical CenterTerminatedNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic...United States
-
Bristol-Myers SquibbNo longer availableNon-squamous Non-Small Cell Lung Cancer | Squamous Non-Small Cell Lung CancerBrazil, Canada
-
Hoffmann-La RocheCompletedNon-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung CancerSpain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
-
European Organisation for Research and Treatment...WithdrawnSquamous Non-small Cell Lung Cancer | Non-Squamous Non-small Cell Lung Cancer
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
Eli Lilly and CompanyWithdrawnMetastatic Squamous Non-Small Cell Lung Cancer | Locally Advanced Squamous Non-Small Cell Lung CancerItaly, Romania, Germany, Belgium, Russian Federation, United States, United Kingdom
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
Clinical Trials on "Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin"
-
Second Xiangya Hospital of Central South UniversityEnrolling by invitationNon-small Cell Lung CancerChina
-
Fudan UniversityNot yet recruiting
-
Anhui Chest HospitalNot yet recruitingCarcinoma, Non-Small-Cell Lung
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruiting
-
Hebei Medical UniversityRecruitingLeptomeningeal Metastasis | Immune Checkpoint Inhibitor | EndostatinChina
-
Chongqing University Cancer HospitalNot yet recruitingNasopharyngeal Carcinoma
-
Sun YanPeking University; Peking University Cancer Hospital & InstituteUnknownHead and Neck NeoplasmsChina
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingGastrointestinal NeoplasmsChina
-
Hairong LiuNot yet recruiting
-
Peking University Third HospitalNot yet recruiting